Skip to Content
MilliporeSigma
All Photos(2)

Key Documents

View All Documentation

857347P

Avanti

VPC 51299

Avanti Research™ - A Croda Brand

Synonym(s):

(R,E)-(3-palmitamido-4-(4-((4-(2,2,2-trifluoroethoxy)pyridin-2-yl)methoxy)phenyl)but-1-en-1-yl)phosphonic acid

Sign Into View Organizational & Contract Pricing

Select a Size

All Photos(2)

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
C34H50 F3N2O6P
CAS Number:
1004787-61-4
Molecular Weight:
670.74
UNSPSC Code:
12352211
NACRES:
NA.25

assay

>99% (TLC)

form

powder

packaging

pkg of 1 × 1 mg (857347P-1mg)

manufacturer/tradename

Avanti Research™ - A Croda Brand

lipid type

phospholipids
cardiolipins

shipped in

dry ice

storage temp.

−20°C

SMILES string

CCCCCCCCCCCCCCCC(N[C@H](CC1=CC=C(OCC2=NC=CC(OCC(F)(F)F)=C2)C=C1)/C=C/P(O)(O)=O)=O

General description

VPC51299 is a potent low micromolar inhibitor containing a vinyl phosphonate head group and possessing a half-life of approximately 90 min in rats when dosed intravenously. Previously developed LPA1/LPA3 receptor antagonists contain a labile phosphate head group which impairs evaluation of scaffold LPA receptor antagonists in vivo. VPC51299 has replaced the phosphate with a more stable head group while retaining potency at both LPA1 and LPA3 to facilitate future in vivo studies of the biological functions of these receptors.[1] This product is covered by Patent Number US 8,283,339 B2. Avanti manufactures this under license from University of Virginia.

Packaging

5 mL Amber Glass Screw Cap Vial (857347P-1mg)

Legal Information

Avanti Research is a trademark of Avanti Polar Lipids, LLC

Storage Class

13 - Non Combustible Solids

wgk_germany

WGK 3

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Development of a phosphatase-resistant, L-tyrosine derived LPA1/LPA3 dual antagonist.
East JE, et al.
MedChemComm, 2, 325-330 (2011)
James E East et al.
MedChemComm, 2(4), 325-330 (2011-12-20)
Lysophosphatidic acid (LPA) is a bioactive compound that has gained attention due to its role in neoplastic diseases. Our group has developed a potent dual LPA1/LPA3 receptor antagonist, VPC51098 (LPA1 IC(50) = 84 nM, LPA1 IC(50) = 48 nM) that

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service